MOMTAZEE JAMES C 4
4 · Roivant Sciences Ltd. · Filed Sep 12, 2025
Insider Transaction Report
Form 4
MOMTAZEE JAMES C
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-09-10+33,726→ 33,726 totalExercise: $13.77Exp: 2035-09-09→ Common Shares (33,726 underlying) - Award
Common Shares
2025-09-10+14,524→ 111,194 total - Other
Common Shares
2025-09-10$13.77/sh−3,282$45,193→ 107,912 total
Footnotes (3)
- [F1]Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.
- [F2]Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.
- [F3]Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date.